S

Syncom Formulations (India) Ltd
NSE:SYNCOMF

Watchlist Manager
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Watchlist
Price: 14.09 INR -0.49% Market Closed
Market Cap: 13.2B INR
Section:
 

Relative Value

The Relative Value of one SYNCOMF stock under the Base Case scenario is hidden INR. Compared to the current market price of 14.09 INR, Syncom Formulations (India) Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SYNCOMF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.7
P/S
P/S
Price to Sales
2.7
vs History
69
vs Industry
28
Median 3Y
3.4
Median 5Y
3.4
Industry
2.7
More Details
23
P/E
P/E
Price to Earnings
23
vs History
69
vs Industry
9
Median 3Y
32.5
Median 5Y
32.5
Industry
21.5
More Details
56.5
P/OCF
P/OCF
Price to OCF
56.5
vs History
23
vs Industry
Median 3Y
-389.5
Median 5Y
-389.5
Industry
16.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-46.8
Median 5Y
-46.8
Industry
23
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
61
vs Industry
15
Median 3Y
4.5
Median 5Y
4.5
Industry
2.3
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
69
vs Industry
29
Median 3Y
3.3
Median 5Y
3.3
Industry
2.9
More Details
7.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.1
vs History
69
vs Industry
19
Median 3Y
9.5
Median 5Y
9.5
Industry
5.6
More Details
20.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.5
vs History
69
vs Industry
10
Median 3Y
27.7
Median 5Y
27.7
Industry
13.2
More Details
22.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
22.4
vs History
69
vs Industry
10
Median 3Y
30.9
Median 5Y
30.9
Industry
16.6
More Details
52.7
EV/OCF
EV/OCF
Enterprise Value to OCF
52.7
vs History
23
vs Industry
Median 3Y
-373.3
Median 5Y
-373.3
Industry
15.8
More Details
91.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
91.7
vs History
23
vs Industry
Median 3Y
-208.3
Median 5Y
-208.3
Industry
19
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
56
vs Industry
14
Median 3Y
4.8
Median 5Y
4.8
Industry
2
More Details

Multiples Across Competitors

SYNCOMF Competitors Multiples
Syncom Formulations (India) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Syncom Formulations (India) Ltd
NSE:SYNCOMF
13.2B INR 2.7 23 20.5 22.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.7B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
213.8B GBP 5 30.6 108.3 158.4
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.5 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
263B USD 4.1 13.8 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13.9 9.7 11.3
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142.1B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
IN
S
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Average P/E: 24.1
23
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.6
37%
0.8
CH
Novartis AG
SIX:NOVN
18.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
3%
4.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
S
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Average EV/EBITDA: 401.4
20.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.7
1%
9.7
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
S
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Average EV/EBIT: 1 713.7
22.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4

See Also

Summary
SYNCOMF intrinsic value, competitors valuation, and company profile.
DCF Valuation
SYNCOMF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SYNCOMF stock valuation using valuation multiples.
Wall Street Estimates
SYNCOMF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SYNCOMF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.